company background image
PEB logo

Pacific Edge ASX:PEB Stock Report

Last Price

AU$0.056

Market Cap

AU$43.5m

7D

7.7%

1Y

-44.0%

Updated

01 Feb, 2025

Data

Company Financials +

PEB Stock Overview

A cancer diagnostics company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. More details

PEB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Pacific Edge Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pacific Edge
Historical stock prices
Current Share PriceNZ$0.056
52 Week HighNZ$0.18
52 Week LowNZ$0.05
Beta1.07
1 Month Change-58.52%
3 Month Change-56.92%
1 Year Change-44.00%
3 Year Change-94.67%
5 Year Changen/a
Change since IPO-96.36%

Recent News & Updates

Recent updates

Shareholder Returns

PEBAU BiotechsAU Market
7D7.7%3.5%1.4%
1Y-44.0%0.06%9.2%

Return vs Industry: PEB underperformed the Australian Biotechs industry which returned 0.1% over the past year.

Return vs Market: PEB underperformed the Australian Market which returned 9.2% over the past year.

Price Volatility

Is PEB's price volatile compared to industry and market?
PEB volatility
PEB Average Weekly Movement27.4%
Biotechs Industry Average Movement9.5%
Market Average Movement7.9%
10% most volatile stocks in AU Market16.3%
10% least volatile stocks in AU Market3.0%

Stable Share Price: PEB's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: PEB's weekly volatility has increased from 20% to 27% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001114Peter Meintjeswww.pacificedgedx.com

Pacific Edge Limited, a cancer diagnostics company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer.

Pacific Edge Limited Fundamentals Summary

How do Pacific Edge's earnings and revenue compare to its market cap?
PEB fundamental statistics
Market capAU$43.46m
Earnings (TTM)-AU$26.11m
Revenue (TTM)AU$20.52m

2.1x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PEB income statement (TTM)
RevenueNZ$22.62m
Cost of RevenueNZ$11.57m
Gross ProfitNZ$11.05m
Other ExpensesNZ$39.84m
Earnings-NZ$28.79m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.035
Gross Margin48.86%
Net Profit Margin-127.26%
Debt/Equity Ratio0.7%

How did PEB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 03:23
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pacific Edge Limited is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBrookline Capital Markets
Gregory MainCredit Suisse
Maxim JacobsEdison Investment Research